Skip to main content
. Author manuscript; available in PMC: 2020 Sep 3.
Published in final edited form as: JCO Precis Oncol. 2020 Apr 30;4:442–465. doi: 10.1200/PO.19.00345

FIG 4.

FIG 4.

Association between BRCA1/2 alteration status and high genome-wide loss of heterozygosity (gLOH-high). The frequency of (A) BRCA1/2, (B) BRCA1, or (C) BRCA2 biallelic, monoallelic, and wild-type cases that were gLOH-high was compared across cancer types. Cancer types with > 50 biallelic BRCA1/2-altered samples were assessed individually, and all other cancer types were grouped together and analyzed as a single group (other). Odds ratios and P values (Fisher’s exact test) were for comparisons between biallelic and wild-type BRCA1/2 cases (see Data Supplement). gLOH-high, was defined as ≥ 16% genome-wide loss of heterozygosity cutoff. CUP, cancers of unknown primary; NSCLC, non–small-cell lung cancer; UC, urothelial cancer.